指南与共识口腔修复与种植

ITI第3组共识报告:种植牙材料与抗骨吸收药物相关结局

Group 3 ITI Consensus Report: Materials and antiresorptive drug-associated outcomes in implant dentistry.
指南 / 共识 · Clin Oral Implants Res · 2023-01-01

本共识报告基于三项系统综述,探讨非钛种植材料、穿黏膜基台材料及影响骨代谢药物对种植牙临床与生物学结局的影响。专家组形成共识:氧化锆可作为钛的替代材料,低剂量抗骨吸收药物不增加早期种植失败率,但高剂量患者需多学科中心严格管理。

要点

  • 氧化锆种植体及穿黏膜部件在5年存活率、边缘骨吸收和探诊深度上与钛相当。
  • 低剂量双膦酸盐治疗不增加早期种植失败率,但长期效果研究不足。
  • 低剂量抗骨吸收药物患者无需药物假期,但需考虑治疗窗口、累积剂量和给药时间。

核心结论

  • 氧化锆种植体在特定适应症中可替代钛种植体,但证据有限,尤其对于两段式设计。
  • 低剂量抗骨吸收药物对早期种植结局无负面影响,但需谨慎随访和支持性护理以预防种植体周围MRONJ和IRS。
  • 高剂量抗骨吸收药物患者种植手术必须在综合多学科中心严格评估。

研究设计与样本

  • 基于三项系统综述的专家组共识,形成共识声明和临床推荐,经全体会议讨论修改后接受。

主要发现

  • 氧化锆作为种植体和穿黏膜部件材料,其种植体存活率、边缘骨吸收和种植体周围探诊深度至5年与钛相当。
  • 氧化锆种植体证据多基于一段式种植体,限制适应症范围。
  • 接受低剂量双膦酸盐治疗的患者早期种植失败率不增加,但长期效果研究不足。
  • 低剂量地诺单抗可能预期类似结局,但尚未充分研究。
  • 低剂量抗骨吸收药物患者种植并发症风险高,推荐在多学科中心严格处理。

关键数值与推荐

  • 基于专家意见,美学区可优先选择氧化锆穿黏膜部件。
  • 低剂量抗骨吸收药物患者考虑种植时,不推荐药物假期,但应考虑具体治疗窗口、累积剂量和给药时间。
  • 必须提供种植体周围支持性护理以预防MRONJ或IRS。
  • 健康种植体在低剂量或高剂量抗骨吸收药物治疗前不应拔除。

临床怎么用

  • 氧化锆种植体可用于特定适应症,尤其一段式设计,美学区穿黏膜部件可优先选择氧化锆。
  • 低剂量抗骨吸收药物患者可接受种植,但需严格随访和支持性护理。
  • 高剂量抗骨吸收药物患者种植手术应在综合多学科中心严格评估后进行。

局限性

  • 氧化锆种植体证据主要基于一段式设计,两段式设计证据有限。
  • 低剂量双膦酸盐的长期效果研究不足,地诺单抗证据不充分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of Working Group 3 was to address the influence of both material- and anti-resorptive drug- related factors on clinical and biological outcomes and complications in implant dentistry. Focused questions were addressed on (a) implant materials other than titanium (alloy)s, (b) transmucosal abutment materials and (c) medications affecting bone metabolism were addressed. MATERIALS AND METHODS: Three systematic reviews formed the basis for discussion in Group 3. Consensus statements and clinical recommendations were formulated by group consensus based on the findings of the systematic reviews. Patient perspectives and recommendations for future research were also conveyed. These were then presented and accepted following further discussion and modifications as required by the plenary. RESULTS: Zirconia is a valid alternative to titanium as material for implant and transmucosal components, allowing soft and hard tissue integration with clinical outcomes-identified by implant survival, marginal bone loss and peri-implant probing depths-up to 5-years comparable to titatnium. However, most of the evidence for zirconia implants is based on 1-piece implants limiting the indication range. Furthermore, based on expert opinion, zirconia transmucosal components might be preferred in the esthetic zone. In patients receiving low-dose bisphosphonate therapy, the rate of early implant failure is not increased, while the long-term effects remain poorly studied. Although it has not been sufficiently addressed, similar outcomes can be expected with low-dose denosumab. A drug holiday is not recommended when considering implant placement in patients treated with low-dose ARD. However, the specific therapeutic window, the cumulative dose and the administration time should be considered. Access to peri-implant supportive care is mandatory to prevent peri-implantitis-related medication-related osteonecrosis of the jaw (MRONJ) or implant-related sequestra (IRS). In patients receiving low-dose anti-resorptive drugs (ARD) therapy, the risk of complications related to implant placement is high, and implant procedures in this specific population should be strictly treated in a comprehensive multidisciplinary center. Finally, healthy dental implants should not be removed before low or high-dose ARD. CONCLUSIONS: Zirconia implants can be an alternative to titanium implants in selected indications. However, the current state of evidence remains limited, especially for 2-piece implant designs. Administration of low-dose ARD did not show any negative impact on early implant outcomes, but careful follow-up and supportive care is recommended in order to prevent peri-implant MRONJ and IRS. Implant placement in high-dose patients must be strictly considered in a comprehensive multidisciplinary center.

来源:Clin Oral Implants Res,查看原文。版权归原作者所有。

引用

  1. Al-Nawas B, Lambert F, Andersen SWM, et al. Group 3 ITI Consensus Report: Materials and antiresorptive drug-associated outcomes in implant dentistry. Clin Oral Implants Res. 2023. PMID: 37750518. doi:10.1111/clr.14135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。